Table 3. Patient characteristics in the FTLD-TDP postmortem cohort.

RIN, RNA integrity number in the frontal cortex; tSTMN2 RNA, truncated STMN2 RNA concentration in the frontal cortex; pTDP-43 protein, phosphorylated TDP-43 protein concentration in the frontal cortex. The sample median (minimum, maximum) is given for continuous variables, and number of cases (percentages) is provided for categorical variables. information was unavailable regarding age at onset (n = 21), survival after symptom onset (n = 21), age at death (n = 1), sex (n = 1), RIN (n = 69), pTDP-43 protein (n = 39), tSTMN2 RNA (n = 55), and TDP-43 subtype (n = 1).

Characteristic	FTLD-TDP (N = 292)
Sex (female)	139 (47.60%)
Age at onset (years)	65 (39.98, 89.62)
Survival after onset (years)	7.00 (0.61, 25.0)
Age at death (years)	72.57 (44.47, 99.56)
Motor neuron disease co-occurence	76 (26%)
TMEM106B rs3173615
CC/TT185	129 (44.2%)
CG/TS185	136 (46.6%)
GG/SS185	27 (9.2%)
TDP-43 subtype
A	150 (51.4%)
B	84 (28.8%)
C	57 (19.5%)
RIN	9.50 (6.10, 10)
pTDP-43 protein	4451 (173.5, 37109)
29-kDa TMEM106B protein	18.59 (0.0, 470.6)
tSTMN2 RNA	560.4 (8.18, 5210)